Rochester General Health System (RGHS) has entered into an expanded relationship with the Mayo Medical Laboratory (MML), a division of the widely respected Mayo Clinic. This new, primary partnership will give RGHS both access to the Mayo Clinic’s extensive menu of reference laboratory tests and clinical expertise and access to innovative tools and resources. This new partnership will support initiatives being developed by the RGHS Department of Pathology & Laboratory Medicine and RGHS Ambulatory Care Laboratory Services to optimize lab test utilization for patients, physicians and other healthcare providers.
“Many healthcare decisions are influenced by lab test results. Laboratory testing costs patients and insurers billions of dollars each year”, said Dawn Riedy MD, RGHS Chief of Pathology. “These tools and initiatives will help us guide ordering providers to choose the most appropriate tests for their patients. There are thousands of testing options, with new tests beginning developed every day, and it’s difficult for healthcare providers to always know exactly which tests will give them the information they need to most effectively care for their patients. Our goal is the right test, for the right patient, at the right time. This is important to both proactively manage healthcare costs and ensure consistently highest quality care.”
RGHS Laboratories perform millions of lab tests each year on-site at Rochester General and Newark Wayne hospitals. Like all local laboratories, RGHS collaborates with a reference laboratory for tests which are rarely ordered or highly specialized in nature. Mayo Medical Laboratories will now serve as the RGHS primary reference laboratory which also means Mayo Clinic physicians and scientists in every specialty laboratory will be available for consultation regarding test selection, methodologies and result interpretation.
“RGHS Labs and our Ambulatory Service Centers already provide a comprehensive menu of high quality lab testing with excellent turnaround times and exceptional customer service, said Bridgette Wiefling MD, Vice President of Clinical Innovation. “ This new partnership with Mayo Clinic takes our lab capabilities to a new level and supports our broader system wide initiatives to provide the very best parent care to all patients across the care continuum. This is a win-win for our community.”
While 99% of laboratory testing will continue to be performed onsite at Rochester General and Newark-Wayne Community Hospitals, this innovative partnership with MML will further enhance our testing capabilities, quality and access for both physicians and their patients.